University of Minnesota. Driven to Discover.
The $275 million deal will make the company the second leading player in the $4 billion global flu vaccine market.
The unanimous resolution creates the first ever special mission geared to a public health crisis.
Vaccine strains overstimulated some kids' immune systems, and CSL said it has taken steps to reduce the risk.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.